22/01/2018 08:00:00

Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients

TOKYO and SAN DIEGO, Jan. 22, 2018 (GLOBE NEWSWIRE) --

Astellas Pharma Inc. (TSE:4503) (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Vical Incorporated (NASDAQ:VICL) announced today that ASP0113, an investigational DNA vaccine being developed for cytomegalovirus (CMV)-seropositive hematopoietic stem cell transplant (HSCT) recipients, did not meet its primary or secondary endpoints in the Phase 3 HELIOS clinical trial. The vaccine was generally well tolerated, with injection-site reactions being the most commonly reported adverse event.

“We are disappointed that the results did not demonstrate a significant improvement in overall survival and reduction in CMV end-organ disease,” said Bernhardt G. Zeiher, president of Development, Astellas. “We would like to thank the patients and clinicians who participated in this important trial.”

The Phase 3 trial was designed to evaluate the efficacy of ASP0113 compared with placebo in CMV-seropositive recipients undergoing an allogeneic stem cell transplant. Efficacy was assessed using a primary composite endpoint of overall mortality and CMV end-organ disease through the first year following the transplant, an endpoint which was not met. Secondary endpoints of time to first protocol-defined CMV viremia and time to first use of adjudicated CMV-specific antiviral therapy also were not met.

“The Phase 3 trial outcome is disappointing,” said Vijay Samant, Vical’s Chief Executive Officer. “Astellas and Vical employees, the investigators and study site personnel did an outstanding job conducting this study, but unfortunately, the vaccine was unable to provide protection against all-cause mortality in this very difficult-to-treat patient population.”

The Phase 3 trial was a 1:1 randomized, double-blind, placebo-controlled study that enrolled a total of 514 CMV seropositive subjects undergoing hematopoietic stem cell transplantation. Randomization was stratified by donor-recipient relatedness and donor CMV serostatus. Subjects were followed for one year post-transplant. For more information about the ASP0113 clinical trial, please visit www.clinicaltrials.gov.

About Cytomegalovirus

CMV is a herpes virus that is estimated to infect more than half of all adults in the United States by age 50, and is even more widespread in developing countries. A healthy immune system typically protects an infected person against CMV disease, but does not prevent or clear latent infection. Individuals whose immune systems are not fully functional are at high risk of CMV reactivation, potentially leading to severe illness or death. Those at greatest risk include HCT and solid-organ transplant recipients, as well as infants born to mothers who first become infected during pregnancy.

About

ASP0113

ASP0113 is an investigational vaccine candidate designed to prevent CMV disease and associated complications in CMV-seropositive HCT recipients. ASP0113 is a bivalent DNA vaccine encoding CMV phosphoprotein 65 and glycoprotein B antigens for induction of both cellular and humoral immune responses, formulated with a proprietary poloxamer-based delivery system. ASP0113 was initially developed by Vical which partnered with Astellas for further development and commercialization. ASP0113 received Orphan Drug Designation in the United States and Europe.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

About Vical

Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com

Astellas Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:

Astellas:

U.S. Media inquiries: Candace Johnson

TEL: +1-224-205-5735 E-MAIL: candace.johnson@astellas.com

Japan Media and Investor Relations inquiries:

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473 

Vical:

Media inquiries: Andrew Hopkins

TEL: +1-858-646-1127  E-MAIL: AHopkins@vical.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
16 Sep
OMXC25
Putin kan lukke samtlige banker i Europa blot ved at sende nogle penge igennem dem, og bagefter lækk..
29
12 Sep
 
Baron84. Med dit køb i Bioporto i kurs 6,09, Matas i kurs +90, Bitcoin i 17.500 og Bavarian i +400, ..
19
14:50
BIOPOR
BioPorto - InvestorDagen 18.september 2018 Jeg deltog til præsentationen af BioPorto ved CFO Ole ..
18
15 Sep
DANSKE
...og jeg kan supplere, man skal ikke tro på mennesker der er maniske eller totalt besatte af en giv..
16
10:58
PNDORA
.....lyder ikke for klogt. Nu har vi været under pres fra shortere i lang tid i Pandora som fik bank..
15
16 Sep
BAVA
Bava var sat op til en næsten perfekt IHS, der ville sende den op i ca. 225.   Men så kommer der lig..
14
13 Sep
OMXC25
Jeg var i London i de år. Jeg kom forbi Lehman Brothers hver morgen og aften ude i Cannary Wharf. De..
14
12 Sep
VELO
  Nu syntes jeg det er interessant og se på hvad var årsagen til Envarsus ikke fik fuld godkendelse ..
14
15 Sep
BAVA
Hvilken af de to links forklarer, at Bavarian faldt 6%? Er det fordi de fik et nyt patent, eller er ..
13
17 Sep
BAVA
dette er en delvis gentagelse af mit indlæg fra weekenden Min tilgang til den er at jeg ikke forstå..
12

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
EF Hutton Launches MeggaCoin
2
Eastmain Resources CEO Updates Uptick Newswire’s Stock Day Podcast on The Company’s Value to Investors as They Hit Major Milestones in Gold Exploration
3
Roche's NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases
4
Iowa’s Smokey D’s BBQ Takes Home Grand Champion Title at 39th American Royal World Series Of Barbecue® Open Competition
5
MIT Sloan Management Review and Boston Consulting Group Study Dispels Five Major Myths About Artificial Intelligence

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 September 2018 19:18:06
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180917.3 - EUROWEB5 - 2018-09-18 20:18:06 - 2018-09-18 19:18:06 - 1000 - Website: OKAY